Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

16 Nov 2009 13:19

RNS Number : 5697C
British SmallerTechCompaniesVCT2PLC
16 November 2009
 



BRITISH SMALLER TECHNOLOGY COMPANIES VCT 2 PLC ("the Company")

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2009

British Smaller Technology Companies VCT 2 plc presents its interim management statement for the quarter ended 30 September 2009. This constitutes the Company's second interim management statement for the financial year ending 31 December 2009, as required by Rule 4.3 of the Disclosure and Transparency Rules. A copy of this interim management statement can be found at www.yfmgroup.co.uk.

The unaudited net asset value per Ordinary share as at 30 September 2009 was 73.0p (30 June 200975.7p). The net asset value as at 30 September 2009 is stated after taking account of the interim dividend of 2.0p per Ordinary share and the special dividend of 2.0p per Ordinary share in respect of the year ended 31 December 2009. These dividends were paid on 2 October 2009 and 30 October 2009 respectively.

The total return at 30 September 2009, calculated by reference to the net asset value per share and the cumulative dividends paid and proposed, increased to 95.0p per share from 93.7p at 30 June 2009.

The number of Ordinary shares in issue at 30 September 2009 was 16,641,257. There were no shares purchased or issued by the Company during the quarter.

Net assets at 30 September 2009 comprised the following:

£000

% of net assets

Unquoted investments at fair value

4,677

38.5%

Quoted investments at bid price

1,023

8.4%

Gilt investments

3,898

32.1%

Total investments

9,598

79.0%

Cash and cash equivalents

1,986

16.3%

Other net current assets (liabilities)

570

4.7%

Net assets

12,154

100.0%

The ten largest investments by valuation at 30 September 2009 were as follows:

£000

% of net assets

Digital Healthcare Limited

1,659

13.6%

Immunobiology Limited

807

6.6%

Primal Pictures Limited

742

6.1%

Pressure Technologies plc

440

3.6%

Silistix Limited

387

3.2%

Waterfall Services Limited

382

3.2%

Harvey Jones Limited

273

2.3%

Patsystems plc

258

2.1%

Ellfin Home Care Limited

150

1.2%

RMS Group Holdings Limited

146

1.2%

Top ten investments

5,244

43.1%

Other investments

456

3.8%

Gilt investments

3,898

32.1%

Total investments

9,598

79.0%

Quoted investments are carried at bid price at 30 September 2009. Unquoted investment are carried at fair value as at 30 September 2009 as determined by the directors.

During the three months ended 30 September 2009 the following significant investment transactions took place (all companies are unquoted except where otherwise indicated):

Disposals

Name of company:

Sale proceeds

£000

Original 

cost

£000

Carrying value at 

30 June 2009

£000

DxS 

1,755*

163

817

ART Technology Group (AiM)

567

244

519

Oxonica (AiM)

3

62

6

RMS Group Holdings 

3

3

3

2,328

472

1,345

* excluding deferred proceeds of £214,000

Performance 

In this period the Company has seen its underlying net asset value decrease by 2.7p per share after the payment of an interim dividend of 2.0p per Ordinary share and a special dividend of 2.0p per Ordinary share. 

The total return, calculated by reference to the net asset value plus cumulative dividend paid and proposed has increased by 1.3p to 95.0p per share, cumulative dividends representing 22.0p per share.

The net asset value currently comprises 48% in cash and gilts and as such the Company is well placed to take advantage of selective investment opportunities as they arise.

The net asset value per share remains significantly in excess of the current share price.

Outlook 

Whilst there remains uncertainty over the speed of recovery in the markets the last quarter has demonstrated that positive realisations are still possible for the right quality of investments. There is some evidence of an increasing search for capital from businesses seeking to expand which your Board believes will translate into increasing investment opportunities over both the short and medium term. This Company is well placed to continue to support these investments and take advantage of investment opportunities that may arise in the short term and is intending to ensure it has sufficient capacity to meet future investment demand. 

16 November 2009

For further information please contact:

David Hall  YFM Private Equity Tel: 0161 832 7603

Jeff Keating Singer Capital Markets Tel: 0203 205 7500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGUGMGGUPBGWQ
Date   Source Headline
6th May 20267:00 amRNSDividend Declaration
20th Apr 202610:01 amRNSAdmission to Trading
1st Apr 20269:00 amRNSIssue of Equity
27th Mar 20264:12 pmRNSTransaction in Own Shares
23rd Mar 202610:45 amRNSPublication of a Supplementary Prospectus
19th Mar 20267:00 amRNSAnnual Financial Report
30th Jan 20267:00 amRNSAdmission of Further Securities to Trading
7th Jan 20269:31 amRNSDirector/PDMR Shareholding
7th Jan 20269:30 amRNSIssue of Equity
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
22nd Dec 20259:13 amRNSTransaction in Own Shares
22nd Dec 20259:13 amRNSTransaction in Own Shares
18th Dec 202512:14 pmRNSClose of Offers to new Applications
18th Dec 202512:14 pmRNSClose of Offers to new Applications
28th Nov 202510:00 amRNSInterim Management Statement
20th Nov 20259:00 amRNSOffer Update
31st Oct 202510:01 amRNSPayment of dividend and issue of Equity
10th Oct 20253:41 pmRNSOffer Update
2nd Oct 20259:00 amRNSOffer Update
25th Sep 20259:04 amRNSPublication of a Prospectus
23rd Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSHalf-year Report
22nd Aug 202510:45 amRNSNew combined offer for subscription
24th Jun 20257:00 amRNSTransaction in Own Shares
23rd Jun 202510:20 amRNSPayment of Dividend and Issue of Equity
13th Jun 20251:30 pmRNSInterim Management Statement
12th Jun 202510:46 amRNSResult of AGM
13th May 202512:54 pmRNSDividend Declaration
1st Apr 20258:02 amRNSDirector/PDMR Shareholding
1st Apr 20258:00 amRNSIssue of Equity
26th Mar 20255:15 pmRNSTransaction in Own Shares
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
18th Mar 20251:00 pmRNSAnnual Financial Report
30th Jan 20259:05 amRNSDirector/PDMR Shareholding
30th Jan 20259:00 amRNSIssue of Equity
27th Jan 20259:21 amRNSPayment of dividend and issue of shares
8th Jan 20252:14 pmRNSClose of Offer to new Applications
8th Jan 20252:13 pmRNSClose of Offer to new Applications
17th Dec 20242:13 pmRNSNominal Capital Reduction
17th Dec 20247:00 amRNSDividend Declaration
16th Dec 20245:08 pmRNSTransaction in Own Shares
29th Nov 20249:00 amRNS3rd Quarter Results
20th Nov 20241:00 pmRNSOffer Update
20th Nov 20241:00 pmRNSOffer Update
12th Nov 20241:52 pmRNSResult of General Meeting
1st Nov 202411:04 amRNSPayment of Dividend and Allotment of Shares
1st Nov 20247:00 amRNSOffer Update
1st Nov 20247:00 amRNSOffer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.